Intracellular Th
Yahoo Finance • 3 months ago
Intra-Cellular Therapies (NASDAQ:ITCI) delivers shareholders fantastic 54% CAGR over 5 years, surging 3.9% in the last week alone
Buying shares in the best businesses can build meaningful wealth for you and your family. And highest quality companies can see their share prices grow by huge amounts. Don't believe it? Then look at the Intra-Cellular Therapies, Inc. (NAS... Full story
Yahoo Finance • 6 months ago
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Intra-Cellular Therapies Inc. In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change... Full story
Yahoo Finance • 10 months ago
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Path To Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) future prospects. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the dis... Full story
Yahoo Finance • 11 months ago
Intra-Cellular Therapies Inc CEO Sharon Mates Sells 191,362 Shares
Sharon Mates, the Chairman, President & CEO of Intra-Cellular Therapies Inc (NASDAQ:ITCI), has sold 191,362 shares of the company on January 18, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $6... Full story
Yahoo Finance • 11 months ago
Intra-Cellular Therapies Inc EVP and General Counsel Michael Halstead Sells 50,000 Shares
Michael Halstead, EVP and General Counsel of Intra-Cellular Therapies Inc (NASDAQ:ITCI), has sold 50,000 shares of the company on January 11, 2024, according to a recent SEC Filing. This transaction has been part of a series of sales by th... Full story
Yahoo Finance • 11 months ago
16 Best Mid Cap Growth Stocks To Buy Now
In this article, we will take a detailed look at the16Best Mid-Cap Growth Stocks To Buy Now. For a quick overview of such stocks, read our article 5Best Mid-Cap Growth Stocks To Buy Now. Investors are hopeful that small- and mid-cap stock... Full story
Yahoo Finance • last year
15 Developed Countries with Lowest Autism Rates
In this article, we will discuss 15 developed countries with lowest autism rates. If you want to skip our discussion on the autism industry, you can go directly to the 5 Developed Countries with Lowest Autism Rates. According to Fortune B... Full story
Yahoo Finance • last year
Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today ann... Full story
Yahoo Finance • last year
Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
Q32023 total revenues increased to $126.2 million, compared to $71.9 million in the same period in 2022 CAPLYTA Q32023 net product sales were$125.8 million, compared to $71.9 million for the same period in 2022, representing a 75%increase... Full story
Yahoo Finance • last year
Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today ann... Full story
Yahoo Finance • last year
Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today an... Full story
Yahoo Finance • last year
Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today an... Full story
Yahoo Finance • 2 years ago
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in 2022, representing a 173% increase Q1 20... Full story
Yahoo Finance • 2 years ago
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today anno... Full story
Yahoo Finance • 2 years ago
Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
Intra-Cellular Therapies Inc. NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous sys... Full story
Yahoo Finance • 2 years ago
The 21 Million-Person Market That Just Drove Intra-Cellular To A 7-Month High
Intra-Cellular said Tuesday its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line. Continue reading... Full story
Yahoo Finance • 2 years ago
Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features
Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the Montgomery Asberg Depression Rating Scale (MADRS) for each patient population including: -combined major depressive disorder (MDD) with mi... Full story
Yahoo Finance • 2 years ago
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
Full year 2022 total revenues of $250.3 million, compared to $83.8 million in 2021 CAPLYTA fourth quarter 2022 net product sales grew to $87.4 million, a 243% increase over the same period in 2021 and a 22% sequential increase over the th... Full story
Yahoo Finance • 2 years ago
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today ann... Full story
Yahoo Finance • 2 years ago
Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today ann... Full story
